Michel Goldman | |
|---|---|
 Goldman in 2014 | |
| Born | 1 January 1955 Brussels, Belgium |
| Awards | Medical Prize Lucien Steinberg (1992) [1] Quinquiennal Prize of the FNRS, Belgium (2000) [2] Doctor Honoris Causa degree, University of Lille 2 (2007) |
| Scientific career | |
| Fields | Immunology, Pharmaceutical R&D, Research Policy |
| Institutions | Université Libre de Bruxelles |
Michel Goldman (born 1 January 1955) is a Belgian medical doctor who specialized in internal medicine and immunology.
Michel Goldman graduated as a medical doctor (1978) from Université Libre de Bruxelles (ULB), Belgium, and received his PhD in medical sciences (1981) from Université de Genève, Switzerland. He is board certified in internal medicine (1984) and clinical biology (1993).
From 1990 to 2008, he heads the Department of Immunology-Hematology-Transfusion at Erasme Hospital in Brussels, and from 2004 to 2009 serves as the first Director of the Institute for Medical Immunology built on the Charleroi campus of ULB, with the support of GSKBiologicals and the Walloon Region.
In 2009, Michel Goldman becomes the first executive director of the Innovative Medicines Initiative (IMI) [3] a joint undertaking between the European Commission and the European Federation of Pharmaceutical Industries and Associations. Managing a budget of €2 billion, he has been responsible for the launch of 59 public-private consortia in areas of major importance, including antimicrobial resistance, Alzheimer's dementia, cancer, diabetes, immuno-inflammatory disorders, autism, chronic pulmonary diseases and drug safety. [4]
Michel Goldman is Professor Emeritus in Immunology at ULB. He is a member of the Board of the Tuberculosis Vaccine Initiative, [5] and of the Board of the Friends of the Global Fund Europe.
Starting from September 2015, Michel Goldman is leading the Institute for Interdisciplinary Innovation in Healthcare (I3h), a ULB centre that has the mission of fostering research, education and outreach networks for the benefit of patients and other stakeholders.
In January 2016 Michel Goldman has been appointed as the Field Chief Editor of Frontiers in Medicine.
Niels Kaj Jerne, FRS was a Danish immunologist. He shared the Nobel Prize in Physiology or Medicine in 1984 with Georges J. F. Köhler and César Milstein "for theories concerning the specificity in development and control of the immune system and the discovery of the principle for production of monoclonal antibodies".
Joseph Leonard Goldstein ForMemRS is an American biochemist. He received the Nobel Prize in Physiology or Medicine in 1985, along with fellow University of Texas Southwestern researcher, Michael Brown, for their studies regarding cholesterol. They discovered that human cells have low-density lipoprotein (LDL) receptors that remove cholesterol from the blood and that when LDL receptors are not present in sufficient numbers, individuals develop hypercholesterolemia and become at risk for cholesterol related diseases, notably coronary heart disease. Their studies led to the development of statin drugs.
Jacques Francis Albert Pierre Miller AC FRS FAA is a French-Australian research scientist. He is known for having discovered the function of the thymus and for the identification, in mammalian species of the two major subsets of lymphocytes and their function.
Ellen Heber-Katz is an American immunologist/regeneration biologist who is professor at Lankenau Institute for Medical Research (LIMR). Her key discovery in mammalian regeneration is the ability of the MRL mouse strain to regenerate wounds without scarring and fully restore damaged tissues. Her work on regeneration has been extended into National Cancer Institute (NCI)-funded studies of novel aspects of breast cancer causation. Her research interests include immunology, regenerative medicine and cancer.
In immunology, an adjuvant is a substance that increases or modulates the immune response to a vaccine. The word "adjuvant" comes from the Latin word adiuvare, meaning to help or aid. "An immunologic adjuvant is defined as any substance that acts to accelerate, prolong, or enhance antigen-specific immune responses when used in combination with specific vaccine antigens."
HLA class II histocompatibility antigen gamma chain also known as HLA-DR antigens-associated invariant chain or CD74, is a protein that in humans is encoded by the CD74 gene. The invariant chain is a polypeptide which plays a critical role in antigen presentation. It is involved in the formation and transport of MHC class II peptide complexes for the generation of CD4+ T cell responses. The cell surface form of the invariant chain is known as CD74. CD74 is a cell surface receptor for the cytokine macrophage migration inhibitory factor (MIF).
Philippe J. Sansonetti is a French microbiologist, professor at the Pasteur Institute and the Collège de France in Paris. He is the director of the Inserm Unit 786 and of the Institut Pasteur laboratory Pathogénie Microbienne Moléculaire.
Nicholas P. Restifo is an American immunologist, physician and educator in cancer immunotherapy. Until July 2019, he was a tenured senior investigator in the intramural National Cancer Institute of the National Institutes of Health at Bethesda, Maryland. Nicholas was an executive vice president of research at Lyell based in San Francisco.
Sanjiv Sam Gambhir was an American physician-scientist. He was the Virginia and D.K. Ludwig Professor in Cancer Research, Chairman of the Department of Radiology at Stanford University School of Medicine, and a professor by courtesy in the departments of Bioengineering and Materials Science and Engineering at Stanford University. Additionally, he served as the Director of the Molecular Imaging Program at Stanford (MIPS), Canary Center at Stanford for Cancer Early Detection and the Precision Health and Integrated Diagnostics Center (PHIND). He authored 680 publications and had over 40 patents pending or granted. His work was featured on the cover of over 25 journals including the Nature Series, Science, and Science Translational Medicine. He was on the editorial board of several journals including Nano Letters, Nature Clinical Practice Oncology, and Science Translational Medicine. He was founder/co-founder of several biotechnology companies and also served on the scientific advisory board of multiple companies. He mentored over 150 post-doctoral fellows and graduate students from over a dozen disciplines. He was known for his work in molecular imaging of living subjects and early cancer detection.
J. (Joseph) Donald Capra is an American immunologist, physician-scientist, and was the 4th full-time president (1997–2007) and later, president emeritus, of the Oklahoma Medical Research Foundation (OMRF) in Oklahoma City, OK. While president, he helped to raise over $100 million and spearheaded major research growth in grants funded and faculty recruited to the institution.
Detlef Schuppan is a German biochemist and physician. He focuses on the diagnosis and treatment of coeliac disease and wheat sensitivity, fibrotic liver diseases and the immunology of chronic diseases and cancer. He is the director of the Institute of Translational Immunology and a professor of internal medicine, gastroenterology, and hepatology at the Medical Center of the Johannes Gutenberg University of Mainz in Germany. He directs the outpatient clinic for coeliac disease and small intestinal diseases. He is also a professor of medicine and a senior visiting scientist at Harvard Medical School.
Michel C. Nussenzweig is a professor and head of the Laboratory of Molecular Immunology at The Rockefeller University and a Howard Hughes Medical Institute investigator. He is a member of both the US National Academy of Medicine and the US National Academy of Sciences.
Bhaskar Saha is an Indian immunologist, cell biologist and a senior scientist at National Centre for Cell Science, Pune. He is known for his contributions in the fields of immunology and cell signaling. He is an elected fellow of two of the major Indian science academies, National Academy of Sciences, India and Indian Academy of Sciences. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards, in 2009, for his contributions to biological sciences.
Miram Merad is a French-Algerian professor in Cancer immunology and the Director of the Marc and Jennifer Lipschultz Precision Immunology Institute (PrIISM) at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY. She is the corecipient of the 2018 William B. Coley Award for Distinguished Research in Basic Immunology and a member of the United States National Academy of Sciences.
Bjarne Bogen is a Norwegian immunologist, inventor and physician. He is widely known for his research on DNA vaccines, autoimmune disorders and cancer immunology.
Duane A. Mitchell, M.D., Ph.D. is an American physician-scientist and university professor. He is currently employed at the University of Florida College of Medicine, in Gainesville, Florida as the Assistant Vice President for Research, Associate Dean for Translational Science and Clinical Research, and Director of the University of Florida (UF) Clinical and Translational Science Institute. He is the Phyllis Kottler Friedman Professor in the Lillian S. Wells Department of Neurosurgery. and Co-Director of the Preston A. Wells, Jr. Center for Brain Tumor Therapy. Dr. Mitchell is also the Founder, President, and Chairman of iOncologi, Inc., a biotechnology company in Gainesville, FL specializing in immuno-oncology.
Uğur Şahin is a German oncologist and immunologist. He is the CEO of BioNTech, which developed one of the major vaccines against COVID-19. His main fields of research are cancer research and immunology.
The MRC Weatherall Institute of Molecular Medicine at the University of Oxford is a research institute located at the John Radcliffe Hospital in Oxford. Founded in 1989 by Sir David Weatherall, the institute focuses on furthering our understanding of clinical medicine at a molecular level. It was one of the first institutes of its kind in the world to be dedicated to research in this area.
Drew Weissman is an American physician-scientist best known for his contributions to RNA biology. His work helped enable development of mRNA vaccines, the best known of which are those for COVID-19 produced by BioNTech/Pfizer and Moderna. Weissman is the inaugural Roberts Family Professor in Vaccine Research, Director of the Penn Institute for RNA Innovation, and professor of medicine at the Perelman School of Medicine at the University of Pennsylvania (Penn). He and his research colleague Katalin Karikó have received numerous awards including the presigious Lasker-DeBakey Clinical Medical Research Award.
George Coukos is a physician-scientist in tumor immunology, professor and director of the Ludwig Cancer Research Lausanne Branch and director of the Department of oncology UNIL-CHUV of the University of Lausanne and the Lausanne University Hospital in Lausanne, Switzerland. He is known for his work on the mechanisms by which tumors suppress anti-cancer immune responses, and the role of the tumor vasculature in that suppression. In addition to his work in ovarian cancer, the combinatorial immune therapies proposed by Professor Coukos have been successfully tested and approved for lung, liver and kidney cancers.
| Authority control: Scientific databases |
|---|
